Wound healing potential of topical bacteriophage therapy on diabetic cutaneous wounds

Wound Repair and Regeneration

Volumn 21, Issue 4, 2013, Pages 595-603

  Mendes, João J ^a,b   Leandro, Clara ^a   Corte Real, Sofia ^a   Barbosa, Raquel ^a   Cavaco Silva, Patrícia ^a,d   Melo Cristino, José ^c   Gõrski, Andrzej ^e   Garcia, Miguel ^a  

^a TechnoPhage SA   (Portugal)

^b Central Lisbon Hospital Center Lisbon ^*  (Portugal)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^d INSTITUTO SUPERIOR DE CIÊNCIAS DA SAÚDE EGAS MONIZ   (Portugal)

^e INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; WOUND HEALING PROMOTING AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL INFECTION; BACTERIOPHAGE; BACTERIUM COLONY; CONTROLLED STUDY; DEBRIDEMENT; DIABETES MELLITUS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MICROBIOLOGICAL PARAMETERS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RAT; SKIN INJURY; STAPHYLOCOCCUS AUREUS; SWINE; WOUND CLOSURE; WOUND HEALING;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADMINISTRATION, CUTANEOUS; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIOPHAGES; COLONY COUNT, MICROBIAL; DIABETES COMPLICATIONS; DISEASE MODELS, ANIMAL; FEASIBILITY STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS PHAGES; RATS; RATS, WISTAR; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS PHAGES; SWINE; WOUND INFECTION;

EID: 84879787064     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/wrr.12056     Document Type: Article

References (41)

1. Jeffcoate WJ, Harding KG,. Diabetic foot ulcers. Lancet 2003; 361: 1545-1551.
2. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004; 39: 885-910.
3. Lipsky BA, Hoey C,. Topical antimicrobial therapy for treating chronic wounds. Clin Infect Dis 2009; 49: 1541-1549.
4. Tascini C, Piaggesi A, Tagliaferri E, Iacopi E, Fondelli S, Tedeschi A, et al. Microbiology at first visit of moderate-to-severe diabetic foot infection with antimicrobial activity and a survey of quinolone monotherapy. Diabetes Res Clin Pract 2011; 94: 133-139.
5. Mendes JJ, Marques-Costa A, Vilela C, Neves J, Candeias N, Cavaco-Silva P, et al. Clinical and bacteriological survey of diabetic foot infections in Lisbon. Diabetes Res Clin Pract 2012; 95: 153-161.
6. Wolcott RD, Rumbaugh KP, James G, Schultz G, Phillips P, Yang Q, et al. Biofilm maturity studies indicate sharp debridement opens a time- dependent therapeutic window. J Wound Care 2010; 19: 320-328.
7. Nelson EA, O'Meara S, Golder S, Dalton J, Craig D, Iglesias C,. Systematic review of antimicrobial treatments for diabetic foot ulcers. Diabet Med 2006; 23: 348-359.
8. Ansaldi M,. Cell biology perspectives in phage biology. Front Biosci (Elite Ed) 2012; 4: 1823-1829.
9. Rossney AS, Pomeroy HM, Keane CT,. Staphylococcus aureus phage typing, antimicrobial susceptibility patterns and patient data correlated using a personal computer: advantages for monitoring the epidemiology of MRSA. J Hosp Infect 1994; 26: 219-234.
10. Burrowes B, Harper DR, Anderson J, McConville M, Enright MC,. Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens. Expert Rev Anti Infect Ther 2011; 9: 775-785.
11. Azeredo J, Sutherland IW,. The use of phages for the removal of infectious biofilms. Curr Pharm Biotechnol 2008; 9: 261-266.
12. Sulakvelidze A, Alavidze Z, Morris JG Jr,. Bacteriophage therapy. Antimicrob Agents Chemother 2001; 45: 649-659.
13. McVay CS, Velasquez M, Fralick JA,. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother 2007; 51: 1934-1938.
14. Soothill JS,. Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa. Burns 1994; 20: 209-211.
15. Wills QF, Kerrigan C, Soothill JS,. Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model. Antimicrob Agents Chemother 2005; 49: 1220-1221.
16. Ryan EM, Gorman SP, Donnelly RF, Gilmore BF,. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. J Pharm Pharmacol 2011; 63: 1253-1264.
17. Council of the European Communities. Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes. Off J Eur Communities 1986; L358: 1-28.
18. Portuguese Agricultural Ministry. Portaria no. 1005/92 of 23 October on the protection of animals used for experimental and other scientific purposes. Diário da República I-Série B 1992; 245: 4930-4942.
19. Institute for Laboratory Animal Research. Guide for the care and use of laboratory animals, 8th ed. Washington, DC: National Academies Press, 2011.
20. Adams M,. Bacteriophages. New York: Interscience Publishers, Inc, 1959.
21. Miller H,. Practical aspects of preparing phage and plasmid DNA: growth, maintenance, and storage of bacteria and bacteriophage. Methods Enzymol 1987; 152: 145-170.
22. Kropinski A, Mazzocco A, Waddell T, Lingohr E, Johnson R,. Enumeration of bacteriophages by double agar overlay plaque assay. In:, Clokie M, Kropinski A, editors. Bacteriophages Methods and protocols, volume 1: isolation, characterization, and interactions. New York: Humana Press, Springer Science + Business Media, 2009: 69-76.
23. Mendes JJ, Leandro CI, Bonaparte DP, Pinto AL,. A rat model of diabetic wound infection for the evaluation of topical antimicrobial therapies. Comp Med 2012; 62: 1-12.
24. Wu K, Huan Y,. Streptozotocin-induced diabetic models in mice and rats. Curr Protoc Pharmacol 2008; 5.47: 1-14.
25. Sullivan PK, Conner-Kerr TA, Hamilton H, Parrish-Smith E, Tefertiller C, Webb A,. Assessment of wound bioburden development in a rat acute wound model-quantitative swab versus tissue biopsy. Wounds 2004; 16: 115-123.
26. Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH,. Manual of clinical microbiology, 8th ed. Washington, DC: ASM Press, 2003.
27. Chapman GH,. A single culture medium for selective isolation of plasma coagulating staphylococci and for improved testing of chromogenesis, plasma coagulation, mannitol fermentation and the Stone reaction. J Bacteriol 1946; 51: 409-410.
28. Brown VI, Lowbury EJ,. Use of improved cetrimide agar medium and other culture methods for Pseudomonas aeruginosa. J Clin Pathol 1965; 18: 752-756.
29. Wareham DW, Gordon NC,. Modifications to CHROMagar Acinetobacter for improved selective growth of multi-drug resistant Acinetobacter baumannii. J Clin Pathol 2011; 64: 164-167.
30. Scherer SS, Pietramaggiori G, Mathews JC, Chan R, Fiorina P, Orgrill DP,. Wound healing kinetics of the genetically diabetic mouse. Wounds 2008; 20: 18-28.
31. Galiano RD, Michaels J, Dobryansky M, Levine JP, Gurtner GC,. Quantitative and reproducible murine model of excisional wound healing. Wound Repair Regen 2004; 12: 485-492.
32. Hirsch T, Spielmann M, Zuhaili B, Koehler T, Fossum M, Steinau HU, et al. Enhanced susceptibility to infections in a diabetic wound healing model. BMC Surg 2008; 8: 5.
33. Kumari S, Harjai K, Chhibber S,. Bacteriophage versus antimicrobial agents for the treatment of murine burn wound infection caused by Klebsiella pneumoniae B5055. J Med Microbiol 2011; 60 (Pt 2): 205-210.
34. Loc Carrillo C, Atterbury RJ, el-Shibiny A, Connerton PL, Dillon E, Scott A, et al. Bacteriophage therapy to reduce Campylobacter jejuni colonization of broiler chickens. Appl Environ Microbiol 2005; 71: 6554-6563.
35. Cairns BJ, Timms AR, Jansen VA, Connerton IF, Payne RJ,. Quantitative models of in vitro bacteriophage-host dynamics and their application to phage therapy. PLoS Pathog 2009; 5: e1000253.
36. Hooton SP, Atterbury RJ, Connerton IF,. Application of a bacteriophage cocktail to reduce Salmonella Typhimurium U288 contamination on pig skin. Int J Food Microbiol 2011; 151: 157-163.
37. Simoes LC, Simoes M, Vieira MJ,. Intergeneric coaggregation among drinking water bacteria: evidence of a role for Acinetobacter calcoaceticus as a bridging bacterium. Appl Environ Microbiol 2008; 74: 1259-1263.
38. Fazli M, Bjarnsholt T, Kirketerp-Moller K, Jorgensen B, Andersen AS, Krogfelt KA, et al. Nonrandom distribution of Pseudomonas aeruginosa and Staphylococcus aureus in chronic wounds. J Clin Microbiol 2009; 47: 4084-4089.
39. Greenhalgh DG,. Models of wound healing. J Burn Care Rehabil 2005; 26: 293-305.
40. Mortensen BL, Skaar EP,. Host-microbe interactions that shape the pathogenesis of Acinetobacter baumannii infection. Cell Microbiol 2012; 14: 1336-1344.
41. Chvapil M, Gaines JA, Chvapil TA, Benson D, Tellez C,. An optimal morphometric method for quantitating wound epithelization. J Surg Res 1988; 44: 266-276.